Paul Hastings is chairman and CEO of OncoMed Pharmaceuticals. Prior to joining OncoMed in 2006, he served in executive-level positions at QLT, Inc., Axys Pharmaceuticals, Chiron BioPharmaceuticals, and LXR Biotechnology. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation; served as vice president, marketing and sales and general manager, Europe for Synergen, Inc.; and served in marketing and sales management positions for Hoffmann-La Roche. He is currently lead director of Pacira Pharmaceuticals and has or currently serves on the boards of Relypsa, Biotechnology Industry Organization, California Life Sciences Association, Proteolix, and ViaCell. He received a B.S. in pharmacy from the University of Rhode Island.